Twist Bioscience Is Rapidly Growing Its Customer Base. Can It Turn a Profit?

Not that long ago, I wrote an article asking how long investors would tolerate the growth-at-all-costs business model of Twist Bioscience(NASDAQ:TWST). Shares have responded by soaring over 200% in 2020. I nailed it. 
The DNA synthesis company has poured money into a rapid business expansion at the expense of profitability and operating cash flow, which has forced it to fund the business through stock offerings. That’s not a sustainable long-term strategy, but it’s one investors and Wall Street…

Click here to view the original article.